BY:Carolina Henriques

Tonix Pharmaceuticals, a company dedicated to developing next-gen medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced its Executive Vice President of Commercial Planning and Development, Ronald Notvest, Ph.D., MBA, will present at the 10th Annual BIO Europe Spring Conference in Sweden.

Notvest’s presentation will provide a corporate update and a general overview of Tonix Pharmaceuticals’ fibromyalgia and PTSD clinical programs. Tonix is currently evaluating the drug candidate TNX-102 SL, an FDA Investigational New Drug, in:

According to a press release, the presentation will be at 4:45 p.m. Central European Time on Tuesday, April 5, at the Kistamässan Convention Center in Stockholm, Sweden.

Tonix Pharmaceuticals is working to develop next-generation medicines for common central nervous system disorders such as fibromyalgia and PTSD. These conditions still have inadequate treatment options for chronic disability and their recurrence rate poses an economic challenge to healthcare providers.

Fibromyalgia is one of the most common musculoskeletal conditions, often misdiagnosed and misunderstood. Patients frequently report suffering from symptoms such as muscle and joint pain, short pain threshold, and fatigue, which can lead to anxiety, depression, and social isolation.

PTSD is a psychological disorder that develops in certain people who have survived shocking, traumatic, or life-threatening events. People with PTSD generally have trouble differentiating from a stressful or dangerous situation and a non-threatening event, causing them to experience multiple symptoms associated with fight-or-flight responses.

PTSD symptoms include flashbacks, nightmares, anxiety, avoiding places that trigger memories of traumatic experiences, depression, memory loss, being easily startled or feeling tense, insomnia, and anger issues.

This is republished article. Originally this article was published by https://fibromyalgianewstoday.com

 

LEAVE A REPLY